Covid-19 and drug therapy, what we learned

COVID-19, the disease associated in December 2019 with the novel coronavirus SARS-CoV-2, was observed for the first time in China and then spread worldwide becoming pandemic. Currently, there is still no licensed specific antiviral treatment for the human coronavirus disease and a vaccine will not b...

Descripción completa

Detalles Bibliográficos
Autores principales: Provenzani, Alessio, Polidori, Piera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203261/
https://www.ncbi.nlm.nih.gov/pubmed/32382873
http://dx.doi.org/10.1007/s11096-020-01049-6
_version_ 1783529845744992256
author Provenzani, Alessio
Polidori, Piera
author_facet Provenzani, Alessio
Polidori, Piera
author_sort Provenzani, Alessio
collection PubMed
description COVID-19, the disease associated in December 2019 with the novel coronavirus SARS-CoV-2, was observed for the first time in China and then spread worldwide becoming pandemic. Currently, there is still no licensed specific antiviral treatment for the human coronavirus disease and a vaccine will not be ready soon. However, based on experience from the use of other antiviral agents to treat similar virusses, some treatment options have been tried with some efficacy. Clinical trials for future therapies are still ongoing. In the meantime, prevention, control, active communication and investment in research are the only ways to overcome this challenge.
format Online
Article
Text
id pubmed-7203261
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-72032612020-05-07 Covid-19 and drug therapy, what we learned Provenzani, Alessio Polidori, Piera Int J Clin Pharm Commentary COVID-19, the disease associated in December 2019 with the novel coronavirus SARS-CoV-2, was observed for the first time in China and then spread worldwide becoming pandemic. Currently, there is still no licensed specific antiviral treatment for the human coronavirus disease and a vaccine will not be ready soon. However, based on experience from the use of other antiviral agents to treat similar virusses, some treatment options have been tried with some efficacy. Clinical trials for future therapies are still ongoing. In the meantime, prevention, control, active communication and investment in research are the only ways to overcome this challenge. Springer International Publishing 2020-05-07 2020 /pmc/articles/PMC7203261/ /pubmed/32382873 http://dx.doi.org/10.1007/s11096-020-01049-6 Text en © Springer Nature Switzerland AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Commentary
Provenzani, Alessio
Polidori, Piera
Covid-19 and drug therapy, what we learned
title Covid-19 and drug therapy, what we learned
title_full Covid-19 and drug therapy, what we learned
title_fullStr Covid-19 and drug therapy, what we learned
title_full_unstemmed Covid-19 and drug therapy, what we learned
title_short Covid-19 and drug therapy, what we learned
title_sort covid-19 and drug therapy, what we learned
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203261/
https://www.ncbi.nlm.nih.gov/pubmed/32382873
http://dx.doi.org/10.1007/s11096-020-01049-6
work_keys_str_mv AT provenzanialessio covid19anddrugtherapywhatwelearned
AT polidoripiera covid19anddrugtherapywhatwelearned

Ejemplares similares